Current situation of invasive fungal disease secondary to chemotherapy in leukemia children and progress of blinatumomab as a bridging therapy
10.3760/cma.j.issn.1673-4408.2024.09.002
- VernacularTitle:白血病儿童化疗后继发侵袭性真菌病的现状及博纳吐单抗桥接治疗的研究进展
- Author:
Dongjie PAN
1
;
Ling CAO
Author Information
1. 北京大学首都儿科研究所教学医院 首都儿科研究所附属儿童医院呼吸内科 100020
- Keywords:
Children;
Leukemia;
Blinatumomab;
Invasive fungal disease
- From:
International Journal of Pediatrics
2024;51(9):582-585
- CountryChina
- Language:Chinese
-
Abstract:
Children with leukemia always experience severe bone marrow suppression following chemotherapy，significantly increasing their susceptibility to invasive fungal disease（IFD），which not only complicates treatment but also leads to higher fatality rates.Temporary interruption of chemotherapy during anti-infection treatment is suggested in order to restore immune function，but this may also results in leukemia relapse.Blinatumomab，a bispecific T-cell engager，has demonstrated benefits as a bridging therapy for children with leukemia and IFD.This article provides a comprehensive overview of the current landscape of IFD secondary to chemotherapy in leukemia children and the relevant researches on blinatumomab as a bridging therapeutic agent，so as to provide more ideas for its treatment.
